IRadimed Corporation (IRMD)
52.32
2.22 (4.43%)
At close: Apr 11, 2025, 3:59 PM
52.29
-0.06%
After-hours: Apr 11, 2025, 04:05 PM EDT
IRadimed Revenue Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 |
|---|---|---|---|---|---|---|---|---|
| MRI Compatible Patient Vital Signs Monitoring Systems Revenue | 5.93M | 5.45M | 6.46M | 14.59M | 6.13M | 4.7M | 6.09M | 5.52M |
| MRI Compatible Patient Vital Signs Monitoring Systems Revenue Growth | +8.73% | -15.65% | -55.71% | +138.04% | +30.49% | -22.83% | +10.28% | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|
| International Revenue | 13.04M | 43.9M |
| International Revenue Growth | -70.30% | n/a |
| United States Revenue | 52.53M | n/a |
| United States Revenue Growth | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 8.39M | 7.76M | 7.58M | 4.81M | 7.6M | 6.48M | 6.26M | 6.92M | 6.36M | 5.92M | 5.31M | 5.79M | 5.65M | 4.84M | 5.03M | 4.81M | 5.28M | 4.48M | 7.38M | 5.3M | 5.53M | 4.91M | 4.66M | 4.52M | 4.2M | 3.97M | 3.59M | 3.95M | 3.72M | 3.8M | 3.51M | 3.47M | 2.82M | 3.22M | 4.5M | 3.54M | 3.45M | 2.88M | 3.09M | 3.06M |
| Selling, General, and Administrative Revenue Growth | +8.08% | +2.40% | +57.55% | -36.70% | +17.33% | +3.48% | -9.52% | +8.78% | +7.48% | +11.45% | -8.21% | +2.48% | +16.69% | -3.90% | +4.68% | -8.84% | +17.78% | -39.27% | +39.28% | -4.24% | +12.71% | +5.29% | +3.03% | +7.79% | +5.80% | +10.35% | -8.99% | +6.30% | -2.31% | +8.25% | +1.19% | +23.26% | -12.43% | -28.49% | +26.96% | +2.77% | +19.61% | -6.73% | +1.09% | n/a |
| Research and Development Revenue | 569.99K | 639.47K | 801.13K | 3.83M | 650.43K | 452.56K | 961.95K | 793.72K | 604.74K | 491.64K | 662.6K | 519.1K | 494.85K | 480.7K | 453.68K | 475.82K | 512.72K | 476.88K | 482.65K | 430.28K | 379.31K | 369.53K | 331.31K | 352.57K | 367.71K | 373.58K | 395.99K | 379.83K | 349.56K | 382.7K | 449.01K | 541.29K | 364.21K | 457.13K | 291.82K | 234.34K | 500K | 518.56K | 403.45K | 342.3K |
| Research and Development Revenue Growth | -10.86% | -20.18% | -79.07% | +488.40% | +43.73% | -52.95% | +21.20% | +31.25% | +23.00% | -25.80% | +27.65% | +4.90% | +2.94% | +5.96% | -4.65% | -7.20% | +7.52% | -1.20% | +12.17% | +13.44% | +2.65% | +11.53% | -6.03% | -4.12% | -1.57% | -5.66% | +4.26% | +8.66% | -8.66% | -14.77% | -17.05% | +48.62% | -20.33% | +56.65% | +24.53% | -53.13% | -3.58% | +28.53% | +17.86% | n/a |
| Sales and Marketing Revenue | 4.52M | 3.8M | 3.48M | 3.83M | 3.33M | 2.86M | 2.78M | 3M | 3.66M | 3.04M | 2.91M | 3.07M | 3.12M | 2.59M | 2.47M | 2.38M | 3.07M | 2.28M | 2.37M | 2.43M | 2.56M | 2.3M | 2.2M | 2.11M | 2.05M | 1.78M | 1.52M | 1.65M | 1.56M | 1.25M | 1.32M | 1.36M | 1.24M | 1.35M | 1.41M | 1.28M | 1.31M | 1.21M | 1.1M | 1.09M |
| Sales and Marketing Revenue Growth | +19.03% | +9.17% | -9.16% | +14.96% | +16.22% | +3.07% | -7.36% | -18.08% | +20.58% | +4.45% | -5.27% | -1.65% | +20.71% | +4.69% | +3.81% | -22.47% | +34.45% | -3.86% | -2.44% | -5.02% | +11.54% | +4.42% | +4.22% | +3.00% | +14.84% | +17.70% | -7.89% | +5.32% | +24.83% | -5.41% | -3.02% | +10.16% | -8.01% | -4.47% | +9.88% | -1.79% | +8.31% | +9.19% | +1.47% | n/a |